Stay updated on BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial

Sign up to get notified when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page remains a 403 Forbidden error page, with the displayed site revision updated from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T19:44:23.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error, replacing the study details with an access-denied screen.
    Difference
    17%
    Check dated 2026-09-22T20:59:15.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Revision updated from v3.6.6 to v3.7.0, indicating a newer page version. This change appears to be a non-content update to the page's template or formatting rather than any study details.
    Difference
    0.1%
    Check dated 2026-09-15T20:56:24.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The page revision tag was updated to v3.6.6, replacing the previous v3.6.5 on the study record.
    Difference
    0.1%
    Check dated 2026-09-01T20:55:53.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.4 to v3.6.5, indicating a new version of the ClinicalTrials.gov page was published. This appears to be a minor update or correction rather than a change to the study data or eligibility criteria.
    Difference
    0.1%
    Check dated 2026-08-11T22:06:28.000Z thumbnail image
  8. Check
    90 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.3 to v3.6.4. This indicates a minor page refresh or metadata update on the study details page without altering the study information.
    Difference
    0.1%
    Check dated 2026-07-21T12:50:55.000Z thumbnail image

Stay in the know with updates to BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.